April 10, 2015

New Preclinical Data on Tumor Treating Fields to be presented at the American Association for Cancer Research Annual Meeting 2015

AACR Annual Meeting 2015 April 10, 2015 08:00 AM Eastern Daylight Time ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure, a commercial stage oncology company, announced today that four preclinical abstracts will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2015 in Philadelphia to be held April 18-22,… Read More
learn more
April 9, 2015

Intersect ENT Appoints Kieran Gallahue and Tony Vernon to Board of Directors

April 09, 2015 07:35 PM Eastern Daylight Time MENLO PARK, Calif.–(BUSINESS WIRE)–Intersect ENT, Inc. (NASDAQ: XENT), a company dedicated to improving the quality of life for patients with ear, nose and throat conditions, today announced the appointment of Kieran T. Gallahue and W. Anthony Vernon to the company’s… Read More
learn more
March 30, 2015

Novocure Announces Japanese Approval of Optune (the NovoTTF-100A System) for Treatment of Recurrent Glioblastoma

Approval provides Japanese recurrent glioblastoma patients with a new, effective and safe treatment option Approval allows for rapid, direct commercial market access in Japan, the world’s second largest medical device market Optune™ (formerly NovoTTF™-100A System) (Photo: Business Wire) March 30, 2015 08:00 AM… Read More
learn more
February 23, 2015

Novocure Enrolls the First Patient in its Phase II STELLAR Trial of Tumor Treating Fields Together with Pemetrexed and Cisplatin or Carboplatin for the Treatment of Malignant Mesothelioma

STELLAR will test the efficacy and safety of Tumor Treating Fields applied to the thorax together with standard of care chemotherapy for treatment of mesothelioma February 23, 2015 08:00 AM Eastern Standard Time ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure, a commercial stage oncology company, announced today that… Read More
learn more
January 12, 2015

Novocure Announces the Completion of Enrollment of its PANOVA Trial of Tumor Treating Fields Plus Gemcitabine for Treatment of Pancreatic Cancer

The PANOVA trial will now be expanded to treat an additional twenty advanced pancreatic cancer patients with concomitant TTFields, gemcitabine and nab-paclitaxel January 12, 2015 10:19 AM Eastern Standard Time ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure, a commercial stage oncology company, announced today that the last patient… Read More
learn more
January 8, 2015

Novocure Announces $100 Million Term Loan Agreement with Pharmakon Advisors

January 08, 2015 08:00 AM Eastern Standard Time ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure, a commercial stage oncology company, announced today that it has entered into a term loan agreement with an investment fund managed by Pharmakon Advisors LP. The agreement provides Novocure with up to $100 million of available… Read More
learn more